Quick Answer
Adaptimmune Therapeutics PLC reported Net Income of -$70.81 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$70.81M | +37.8% |
| 2023 | -$113.87M | +31.2% |
| 2022 | -$165.46M | -4.7% |
| 2021 | -$158.09M | -21.5% |
| 2020 | -$130.09M | +5.2% |
| 2019 | -$137.16M | -43.6% |
| 2018 | -$95.51M | -36.2% |
| 2017 | -$70.14M | +2.0% |
| 2016 | -$71.58M | -224.5% |
| 2015 | -$22.06M | -90.1% |
| 2014 | -$11.60M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$30.34M | -143.6% | +36.2% |
| March 31, 2025 | -$47.58M | +1.9% | -170.1% |
| September 30, 2024 | -$17.62M | +61.4% | -125.3% |
| June 30, 2024 | $69.52M | +425.0% | +243.3% |
| March 31, 2024 | -$48.50M | -4781.8% | -6.4% |
| September 30, 2023 | -$45.60M | -10.1% | -113.2% |
| June 30, 2023 | -$21.39M | +52.0% | -2164.6% |
| March 31, 2023 | $1.04M | +102.1% | +102.5% |
- Adaptimmune Therapeutics PLC showed an increase of +37.8% in Net Income compared to the prior fiscal year.
- Over the 2014–2024 period, Adaptimmune Therapeutics PLC’s net income has declined by 510.4% (from -$11.60 million to -$70.81 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: